Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Vaccines

Free Subscription 20.10.2025 1 Ann Intern Med 3 BMJ 1 Clin Infect Dis 2 J Infect Dis 1 J Pediatr 2 Nat Immunol 2 Nat Med 1 Pediatr Infect Dis J 2 PLoS Comput Biol 1 PLoS Med 3 PLoS One 23 Vaccine

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Intern Med

1. VIELOT NA, Jonsson Funk M, Sturmer T, Fix J, et al
   Effectiveness of Recombinant Herpes Zoster Vaccine in the U.S. Medicare Population, 2018 to 2019, by Immunocompetence and Prior Receipt of Live Zoster Vaccine.
   Ann Intern Med. 2025 Oct 14. doi: 10.7326/ANNALS-24-02409.
   PubMed         Abstract available
   
   

   
   BMJ

2. YANG YT
   A radical approach to improving vaccine uptake.
   BMJ. 2025;391:r2159.
   PubMed        
   
   
3. MAHASE E
   US vaccine misinformation is having "frightening" ripple effect in Europe, leaders warn.
   BMJ. 2025;391:r2167.
   PubMed        
   
   
4. TANNE JH
   CDC working group plans to review US child vaccines as thousands of health staff are fired in government shutdown.
   BMJ. 2025;391:r2148.
   PubMed        
   
   

   
   Clin Infect Dis

5. GAGLANI M, Raiyani C, Murthy K, Smith M, et al
   Absolute and Relative Effectiveness of Cell- and Egg-based Quadrivalent Inactivated Influenza Vaccine Products from 2014-2015 to 2018-2019 seasons, U.S. Flu VE Network.
   Clin Infect Dis. 2025 Oct 16:ciaf579. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Infect Dis

6. HOFSINK Q, Lissenberg-Witte BI, Haggenburg S, Goorhuis A, et al
   COVID-19 Vaccine Effectiveness in Patients with Hematologic Malignancies: a Nationwide Cohort Study.
   J Infect Dis. 2025 Oct 14:jiaf523. doi: 10.1093.
   PubMed         Abstract available
   
   
7. FRUTOS AM, Tenforde MW, Sundaresan D, Naleway AL, et al
   Influenza-associated hospitalization rates by underlying conditions, 2016-17 to 2019-20: A retrospective cohort study.
   J Infect Dis. 2025 Mar 28:jiaf164. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Pediatr

8. SOMEKH E, Haddad J, Bali D, Giardino I, et al
   The European Vaccination Challenge: Stemming the Resurgence of Vaccine-Preventable Diseases.
   J Pediatr. 2025 Oct 9:114844. doi: 10.1016/j.jpeds.2025.114844.
   PubMed        
   
   

   
   Nat Immunol

9. KHLEIF SN, Gupta S
   Cancer vaccines as enablers of immunotherapy.
   Nat Immunol. 2025 Oct 16. doi: 10.1038/s41590-025-02308.
   PubMed         Abstract available
   
   
10. AKHTAR A, Styles TM, Gu C, Leon AN, et al
    Influenza vaccine based on AS03-adjuvanted chimeric HA induces long-lived stalk-specific plasma cells in bone marrow and lymph nodes of nonhuman primates.
    Nat Immunol. 2025 Oct 15. doi: 10.1038/s41590-025-02309.
    PubMed         Abstract available
    
    

    
    Nat Med

11. KEELEY AJ, Camara FE, Armitage EP, de Crombrugghe G, et al
    Early-life serological profiles and the development of natural protective humoral immunity to Streptococcus pyogenes in a high-burden setting.
    Nat Med. 2025 Aug 8. doi: 10.1038/s41591-025-03868.
    PubMed         Abstract available
    
    
12. 
    Rotavirus vaccine reduces gastroenteritis hospitalizations in Indian children.
    Nat Med. 2025 Oct 15. doi: 10.1038/s41591-025-04034.
    PubMed        
    
    

    
    Pediatr Infect Dis J

13. PLOTKIN SA
    Can We Have Better Influenza Vaccines?
    Pediatr Infect Dis J. 2025 Oct 17. doi: 10.1097/INF.0000000000005022.
    PubMed        
    
    

    
    PLoS Comput Biol

14. FU F, Zhuo R, Chen X
    Social imitation dynamics of vaccination driven by vaccine effectiveness and beliefs.
    PLoS Comput Biol. 2025;21:e1013586.
    PubMed         Abstract available
    
    
15. MANNA A, Karsai M, Perra N
    Social inequalities in vaccine coverage and their effects on epidemic spreading.
    PLoS Comput Biol. 2025;21:e1013585.
    PubMed         Abstract available
    
    

    
    PLoS Med

16. KAWAMOTO A, Hashida M, Ishida K, Furihata K, et al
    Immunogenicity and safety of DS-5670d, an omicron XBB.1.5-targeting COVID-19 mRNA vaccine: A phase 3, randomized, active-controlled study.
    PLoS Med. 2025;22:e1004499.
    PubMed         Abstract available
    
    

    
    PLoS One

17. BEKUMA TT, Seme A, Ahmed S, Abera M, et al
    Correction: Level and determinants of pentavalent vaccine dropout during infancy: A hierarchical analysis of community-level longitudinal study.
    PLoS One. 2025;20:e0334536.
    PubMed         Abstract available
    
    
18. CHOU HH, Chu PY, Wu YH, Feng C, et al
    Health impact and cost-effectiveness analysis of gender-neutral versus female-only 9-valent human papillomavirus vaccination in Taiwan.
    PLoS One. 2025;20:e0333757.
    PubMed         Abstract available
    
    
19. HOSSEN MT, Alam MSB, Islam MS, Montomoli E, et al
    Impact of the COVID-19 pandemic on the routine immunization system in Bangladesh.
    PLoS One. 2025;20:e0334503.
    PubMed         Abstract available
    
    

    
    Vaccine

20. WILLIAMS LR, Voysey M, Pollard AJ, Grassly NC, et al
    A statistical method for evaluating vaccine-induced immune correlates of protection against infection and disease progression: application to the ChAdOx1-S nCoV-19 phase 3 trial.
    Vaccine. 2025;67:127856.
    PubMed         Abstract available
    
    
21. HARA-HUBBARD KK, Beaulieu A, Mendiola A, Gandhi P, et al
    Strategies for addressing COVID-19 vaccine equity with intermediaries, prevention research centers, and the vaccine confidence network.
    Vaccine. 2025;60 Suppl 1:127847.
    PubMed         Abstract available
    
    
22. PEIXOTO DE MIRANDA EJF, de Sousa Moreira JA, da Silva Braga R, Silveira DHR, et al
    Randomized, double-blind, placebo-controlled, phase 3 trial to demonstrate lot-to-lot consistency of 3 lots of the simplified formulation of Butantan-dengue vaccine.
    Vaccine. 2025;66:127836.
    PubMed         Abstract available
    
    
23. COLLINS C, Ratshisusu L, Modise LM, Simani OE, et al
    Hepatitis B virus infection and vaccine coverage among children living with HIV, HIV-exposed uninfected, and HIV-unexposed uninfected children in the Western Cape, South Africa.
    Vaccine. 2025;66:127843.
    PubMed         Abstract available
    
    
24. CARTER AS, Steele D, John J, Saha S, et al
    Advancing typhoid conjugate vaccine implementation in Asia: Regional policy priorities.
    Vaccine. 2025;66:127848.
    PubMed         Abstract available
    
    
25. BAZZUCCHI M, Rossini E, Cavadini P, Bertasio C, et al
    Genome sequence of the Myxoma virus Borghi vaccine strain.
    Vaccine. 2025;66:127835.
    PubMed         Abstract available
    
    
26. IVERSEN EF, Rahimic AHF, Frattari GS, Rosas-Umbert M, et al
    TCR bias drives development of dominant vaccine-induced CD8+ T cell responses which can be redirected toward cellular targets.
    Vaccine. 2025;66:127851.
    PubMed         Abstract available
    
    
27. VAN RIJN PA, Wernery U, Feddema AJ, Maris-Veldhuis MA, et al
    Corrigendum to "Development of African horse sickness disabled infectious single animal (DISA)-DIVA vaccine platform applied for all nine serotypes" [Vaccine 64 (2025) 127772].
    Vaccine. 2025;66:127839.
    PubMed        
    
    
28. GE Y, Zahid A, Kuchur R, Martinez L, et al
    Using machine learning models to predict vaccine hesitancy: a showcase of COVID-19 vaccine hesitancy in rural populations during the pandemic.
    Vaccine. 2025;66:127799.
    PubMed         Abstract available
    
    
29. RACCAGNI AR, Morsica G, Reali P, Lolatto R, et al
    Long-term protection and response to a booster dose after primary hepatitis B vaccination in people under pre-exposure prophylaxis for HIV infection.
    Vaccine. 2025;66:127825.
    PubMed         Abstract available
    
    
30. NICHOLLS EJ, Onyango D, Kolodin V, Ottaway Z, et al
    The social lives of the SARS-CoV-2 vaccines: A qualitative study of vaccine understandings and decision-making among people of Black ethnicities in London, UK.
    Vaccine. 2025;66:127802.
    PubMed         Abstract available
    
    
31. DOMINGO JL
    Differentiating COVID-19 vaccine-related adverse events from long COVID: A comprehensive review of clinical manifestations, pathophysiology, and diagnostic approaches.
    Vaccine. 2025;66:127842.
    PubMed         Abstract available
    
    
32. DE MELO ARAUJO AC, Frugoli AG, de Sena Goncalves JE, Percio J, et al
    Monitoring strategies after the incorporation of vaccines into national immunization programs: a systematic review.
    Vaccine. 2025;66:127850.
    PubMed         Abstract available
    
    
33. PIRES C
    Influenza vaccine hesitancy in the elderly: Where do we stand?
    Vaccine. 2025;66:127831.
    PubMed         Abstract available
    
    
34. KALIAPPAN A, Ramakrishnan S, Panwar K, Naveen D, et al
    Triple-TLR agonists' adjuvanted inactivated Newcastle disease virus vaccine promotes effective Th1/Th2 immune responses and affords protective efficacy in chickens.
    Vaccine. 2025;66:127846.
    PubMed         Abstract available
    
    
35. BELMONTE M, Kusi KA, Kyei-Baafour E, Ofori EA, et al
    Immunogenicity of HLA-restricted peptide vaccine candidates delivered by self-assembling protein nanoparticle (SAPN) technology.
    Vaccine. 2025;66:127832.
    PubMed         Abstract available
    
    
36. HANSEN BT, Ostlie IB, Greve-Isdahl M, Gleditsch RN, et al
    Determinants of parental readiness for childhood vaccination: experiences, information, sociodemographics and adherence.
    Vaccine. 2025;66:127809.
    PubMed         Abstract available
    
    
37. WANG X, Shang S, Zou T, Hu Y, et al
    Drivers of herpes zoster vaccine hesitancy in adults aged 50 and above: A machine learning approach.
    Vaccine. 2025;66:127838.
    PubMed         Abstract available
    
    
38. RAFFL S, Springer DN, Aberle SW, Florian DM, et al
    Tick-borne encephalitis: Burden of disease and impact of vaccination, Austria (2000-2024).
    Vaccine. 2025;66:127854.
    PubMed         Abstract available
    
    
39. YEO D, Lee K, Jo Y, Lee S, et al
    Long-term effectiveness of live zoster vaccine against herpes zoster and related complications: a nationwide emulated target trial in South Korea.
    Vaccine. 2025;66:127824.
    PubMed         Abstract available
    
    
40. YAMAGUCHI Y, Amiya S, Inokuchi S, Nagao S, et al
    Distinct trajectories of humoral immune responses after SARS-CoV-2 mRNA vaccination in autoimmune inflammatory rheumatic diseases: A group-based trajectory analysis.
    Vaccine. 2025 Oct 12:127771. doi: 10.1016/j.vaccine.2025.127771.
    PubMed         Abstract available
    
    
41. RAMAY BM, Yoder J, Castillo C, Fahsen N, et al
    Assessing effects of pneumococcal vaccination (PCV13) and rotavirus vaccination (RV) on colonization with extended-spectrum cephalosporin-resistant enterobacterales (ESCrE) in guatemalan children.
    Vaccine. 2025;66:127852.
    PubMed         Abstract available
    
    
42. HOU Y, Zarodkiewicz P, Cortazar JT, Stoner D, et al
    Protective efficacy of two novel Klebsiella pneumoniae vaccine antigens, LysM/BON and OMPP1, in a murine model.
    Vaccine. 2025;66:127844.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.